0 9 2004 75		PTO/SB/21 (01-03) Approved for use through 04/30/2003. OMB 0651-0031 and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person	s are required to respond to a collection Application Number	on of information unless it displays a valid OMB control number. 10/700,599
TRANSMITTAL	Filing Date	November 4, 2003
FORM	First Named Inventor	Bohrmann et al.
(to be used for all correspondence after initial filing)	Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	21459 US
ENCI	LOSURES (Check all that	(apply)
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Addre Terminal Disclaimer Request for Refund CD, Number of CD(s)	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information
F:	F APPLICANT, ATTORN	EY, OR AGENT
Firm or Individual Signature February 5, 2004	Di Pleion	
	CATE OF TRANSMISSION	
I hereby certify that this correspondence is being transmitted to mail in an envelope addressed to: Commissioner for Patents, I	o the USPTO or deposited with the Ur P.O. Box 1450, Alexandria, VA 2231	nited States Postal Service with sufficient postage as first class on this date February 5, 2004
Typed or printed Kimberly J. Prior		
Signature Sembell	yther	Date February 5, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventors: Bohrmann, et al.

Serial No. 10/700,599, filed November 4, 2003

(Ref. No. 21459 US)

For: QUANTIFICATION OF BETA AMYLOID

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 February 5, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents B1 and C1 to C18, listed on Form PTO-1449 are enclosed.

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 10/700,599 Filed: November 4, 2003

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application no fee is due.

Respectfully submitted,

Attorney for Applicant(s)

Kimberly J. Prior (Reg. No. 41,483) 340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-6208

Telefax: (973) 235-2363

138743

FEB 0 9 T	MI ST
•	Sheet
•	<u> </u>

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known 10/700,599 **Application Number** November 4, 2003 Filing Date First Name Inventor Bohrmann, et al.

(Use several sheets if necessary)

21459 US of 2 Attorney Docket Number

U.S. PATENT DOCUMENTS

Examiner Initials'	Cite No.¹	U.S. Paten	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
	A				

FOREIGN PATENT DOCUMENTS

Examiner	Cite	Foreign Patent Document		ument	Name of Patentee or	Date of Publication of Cited Document	T ^e
Initials'	No.1	Office ³	Number	Kind Code ⁵ (if known)	Applicant of Cited Document	MM-DD-YYYY	
	B1	EP 0 6	541 861		F.Hoffmann-La Roche AG	03/08/1995	

NON PATENT LITERATURE DOCUMENTS

NON FATENT LITERATURE DOCUMENTS				
Examiner Initials'	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
-	C1	Schutze et al. (1998) Identification of expressed genes by laser-		
		mediated manipulation of single cells, Nature Biotechnology 16:737-742		
	C2	Simone et al. (1998) Laser-capture microdissection: opening the		
		microscopic frontier to molecular analysis, TIG 14:272-276		
	C3	Teller, J. K. et al., Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome Nat. Med. 1996, 2, 93-95		
	C4	Kuo, Y. M. et al., Water-soluble ABeta (N-40, N42) oligomers in Normal and Alzheimer Disease Brains, J. Biol. Chem. 1996, 271, 4077-4081		
	C5	J. Naslund, A. Schierhorn, U. Hellman, L. Lannfelt, AD Roses, LO Tjernberg, J. Silberring, SE Gandy, B. Winblad, PG gard, C. Nordstedt, and L. Terenius (1994) Relative Abundance of Alzheimer ABeta Amyloid Peptide Variants in Alzheimer Disease and Normal Aging, PNAS 91:8378-8382		
	C6	Burdick, D. et al., Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs, J. Biol. Chem. 1992, 267, 546-554		
	C7	Barrow, C. J. et al., Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra, J. Mol. Biol. 1992, 225, 1075-1093		
Examiner		Date Considered		
Signature	<u> </u>			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this

form with next communication to applicant.

*Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation or abstract is attached.

9	2004	٥ <u>)</u> بيرا					
Substitute for form 1449A/PTO					Complete if Known		
	18th	INFORM	IATION	DISCLOSURE	Application Number	10/700,599	
B	DEMAR	STATEN	MENT B	Y APPLICANT	Filing Date	November 4, 2003	
		(Use s	everal shee	ets if necessary)	First Name Inventor	Bohrmann, et al.	
	Sheet	2	of	2	Attorney Docket Number	21459 US	

NON PATENT LITERATURE DOCUMENTS

0.1.	NON PATENT LITERATURE I		T ²			
No.1	item (book, magazine, journal, serial, symposium catalog publisher, city and/or country where published	, etc.), date, page(s), volume-issue number(s),	1.			
C8	J. Stults et al., Simplification of High-	Energy Collision Spectra of				
	1703-1708	_				
C9	B. Spengler et al., Peptide sequencing	of charged derivatives by				
	postsource decay MALDI mass spectro	ometry, Int. J. Mass Spectrom.				
	1997, 169-170, 127-140					
C10	Z. Huang et al., Protein Sequencing by	Matrix-Assisted Laser				
	Desorption Ionization-Postsource Dec	ay-Mass Spectrometry Analysis				
	of the N-Tris (2,4,6-trimethoxyphenyl)phosphine-Acetylated Tryptic					
C11	Staudenmann W. and James P. in Proteome Research: Mass					
	Spectrometry (P. James, Ed) Springer Verlag, Berlin (2001) 143-166					
C12						
	Ouagazzal A.M. and Higgins G.A., Double transgenic mice					
	1 0					
'	deficits and amyloid deposits in discrete brain regions, Soc. Neurosci.					
			<u> </u>			
C13						
	_	d Fibrils, Neurobiology of Aging				
			<u> </u>			
C14	Selkoe D.J. (2001) Alzheimer's Disease: Genes Proteins & Therapy,					
	Physiological Reviews 81: 741-766					
C15	Kirschner D.A. et al., J. Proc. Natl. Acad. Sci. USA 1987, Vol. 84,					
	6953-6957					
C16	Srinivasan, R. (1986) Science 234:559-565					
C17	Doebeli et al. (1995) Biotechnology 13:988-993					
C18 Ida et al. (1996) J. Biol. Chem. 271:22908-22914						
L Signature		DATE CONSIDERED	L			
	C10 C11 C12 C13 C14 C15 C16 C17 C18	Cite No.1 Include name of the author (in CAPITAL LETTERS), tititem (book, magazine, journal, serial, symposium catalog publisher, city and/or country where published C8 J. Stults et al., Simplification of High-Peptides by Amino-Terminal Derivation 1703-1708 C9 B. Spengler et al., Peptide sequencing postsource decay MALDI mass spectron 1997, 169-170, 127-140 C10 Z. Huang et al., Protein Sequencing by Desorption Ionization-Postsource Decorption Ionization-Postsource Decorption Ionization-Postsource Decorption Staudenmann W. and James P. in Protein Spectrometry (P. James, Ed) Springer C12 Richards J. G., Ozmen L., Brockhaus J. Jacobsen, H., Huber G.S, Bluethmann Ouagazzal A.M. and Higgins G.A., Douverexpressing hAPPswe and hPSmut deficits and amyloid deposits in discrete Abstr. 2001, Vol. 27, Program No. 540 C13 Carter et al. (1998), A Model for Structure Congo Red to Alzheimer Beta-Amyloid 19: 37-40 C14 Selkoe D.J. (2001) Alzheimer's Disease Physiological Reviews 81: 741-766 C15 Kirschner D.A. et al., J. Proc. Natl. Act 6953-6957 C16 Srinivasan, R. (1986) Science 234:559 C17 Doebeli et al. (1995) Biotechnology 13: 13. 13. 13. 13. 14. 14. 14. 14. 14. 14. 14. 14. 14. 14	 Cite No.¹ Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.). date, page(s), volume-issue number(s), publisher, eity and/or country where published C8 J. Stults et al., Simplification of High-Energy Collision Spectra of Peptides by Amino-Terminal Derivatization, Anal. Chem. 1993, 65, 1703-1708 C9 B. Spengler et al., Peptide sequencing of charged derivatives by postsource decay MALDI mass spectrometry, Int. J. Mass Spectrom. 1997, 169-170, 127-140 C10 Z. Huang et al., Protein Sequencing by Matrix-Assisted Laser Desorption Ionization-Postsource Decay-Mass Spectrometry Analysis of the N-Tris (2,4,6-trimethoxyphenyl)phosphine-Acetylated Tryptic Digests*1, Anal. Biochem. 1999, 268, 305-317 C11 Staudenmann W. and James P. in Proteome Research: Mass Spectrometry (P. James, Ed) Springer Verlag, Berlin (2001) 143-166 C12 Richards J. G., Ozmen L., Brockhaus M., Bohrmann B., Malherbe P., Jacobsen, H., Huber G.S, Bluethmann H., Kew J.N.C., Kemp J.A. Ouagazzal A.M. and Higgins G.A., Double transgenic mice overexpressing hAPPswe and hPSmut show age-dependent cognitive deficits and amyloid deposits in discrete brain regions, Soc. Neurosci. Abstr. 2001, Vol. 27, Program No. 546.7 C13 Carter et al. (1998), A Model for Structure-Dependent Binding of Congo Red to Alzheimer Beta-Amyloid Fibrils, Neurobiology of Aging 19: 37-40 C14 Selkoe D.J. (2001) Alzheimer's Disease: Genes Proteins & Therapy, Physiological Reviews 81: 741-766 C15 Kirschner D.A. et al., J. Proc. Natl. Acad. Sci. USA 1987, Vol. 84, 6953-6957 C16 Srinivasan, R. (1986) Science 234:559-565 C17 Doebeli et al. (1995) Biotechnology 13:988-993 C18 Ida et al. (1996) J. Biol. Chem. 271:22908-22914 			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. *Applicant is to place a check mark here if English language Translation or abstract is attached.